Search Results
Jul 16, 2026, 06:59 ET Controlled-release Fertilizers Market worth $3.61 billion by 2031- Exclusive Report by MarketsandMarkets™
integrating nitrogen stabilizers into their CRF offerings to meet the dual objectives of productivity and environmental stewardship. As awareness of these benefits spreads among farmers, nitrogen-stabilized fertilizers continue to capture a substantial portion of the CRF market.Request Sample Pages:
More news about: MarketsandMarkets
Jul 07, 2026, 06:30 ET NEVADA KING INTERCEPTS 4.68 G/T AU OVER 7.3M AND 1.00 G/T AU OVER 26.8M NEAR SURFACE AND BOTTOMING IN MINERALIZATION AT EAST RIDGE TARGET
RC and RAB samples from the Atlanta Project are split at the drill site and placed in cloth and plastic bags utilizing a nominal 2kg sample weight. CRF standards, blanks, and duplicates are inserted into the sample stream on-site on a one-in-twenty sample basis, meaning all three inserts are included
More news about: Nevada King Gold Corp.
Jul 01, 2026, 16:05 ET Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
factor type 1 receptor (CRF1) antagonist that reduces and controls excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 16:05 ET Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces and controls excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 08:35 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces and controls excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary has
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 08:30 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces and controls excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary has
More news about: Neurocrine Biosciences, Inc.
Jun 03, 2026, 08:30 ET Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces and controls excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary
More news about: Neurocrine Biosciences, Inc.
May 28, 2026, 08:00 ET Clymb Clinical is pleased to announce Data Mapper™ - an AI-driven, web-based platform that streamlines SDTM and ADaM mapping as part of the expanding Clymbr Hub™ ecosystem
Mapper™, the latest addition to the Clymbr Hub™, enables statistical programmers to ingest clinical study documents and metadata (including Protocol, CRF, SAP, EDC and external data) to automatically generate CDISC SDTM mapping specifications and ADaM derivation frameworks. The platform provides an intuitive,
More news about: Clymb Clinical
May 06, 2026, 16:00 ET Keeping Local Restaurants Cooking: The PG&E Corporation Foundation Funds Restaurants Care Resilience Grants
California Restaurant Foundation's (CRF)
More news about: PG&E Corporation
May 06, 2026, 08:30 ET Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces and controls excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary
More news about: Neurocrine Biosciences, Inc.
May 05, 2026, 16:01 ET Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
evaluating the safety and tolerability of NBIP-'2118 in adult participants. NBIP-'2118 is an investigational corticotropin-releasing factor 2 receptor (CRF2) peptide agonist and a potential first-in-class therapy for obesity.Presented new real-world evidence demonstrating that adult patients
More news about: Neurocrine Biosciences, Inc.
May 04, 2026, 07:30 ET Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
"This program represents an important step in applying Neurocrine's expertise in CRF biology to treat metabolic disease," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "CRF2 agonism is a promising and differentiated mechanism with the potential to address key
More news about: Neurocrine Biosciences, Inc.
May 01, 2026, 16:05 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces and controls excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary
More news about: Neurocrine Biosciences, Inc.
Apr 28, 2026, 06:30 ET NEVADA KING DOUBLES PHASE 4 DRILL PROGRAM TO 40,000 METRES, PROVIDES ASSAY RESULTS FROM SILVER PARK, AND A PROJECT WIDE PERMITTING UPDATE
RC and RAB samples from the Atlanta Project are split at the drill site and placed in cloth and plastic bags utilizing a nominal 2kg sample weight. CRF standards, blanks, and duplicates are inserted into the sample stream on-site on a one-in-twenty sample basis, meaning all three inserts are included
More news about: Nevada King Gold Corp.
Apr 22, 2026, 16:05 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces and controls excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary
More news about: Neurocrine Biosciences, Inc.
Apr 07, 2026, 10:27 ET BayCare Contributes Half a Billion in Community Benefit in 2025
broke ground for a new Central Receiving Facility (CRF), also the first of its kind in Pasco County, to provide assessment, intervention and referrals for individuals experiencing mental health or substance
More news about: BayCare Health System
Feb 17, 2026, 08:00 ET Clymb Clinical Announces the Release of the Clymbr Hub - a unified platform for SAP, TFL and CSR Automation
enabling biostatistics teams to move from protocol and CRF to a structured, review‑ready SAP with greater speed and consistency. Users can automatically generate core SAP sections using protocol objectives, estimands, endpoints, visit schedules, and CRF design—reducing manual copy‑paste, improving alignment,
More news about: Clymb Clinical
Feb 11, 2026, 16:01 ET Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
long-term value creation across core therapeutic areas and announced the strategic expansion and diversification of the corticotropin releasing factor (CRF) platform as a foundation for a new class of medicines targeting metabolic diseases, including obesity.Announced the initiation of a Phase 2
More news about: Neurocrine Biosciences, Inc.
Feb 10, 2026, 13:18 ET eClinical Solutions Market to Surpass USD 35.76 Billion by 2032, Fueled by AI-Driven Clinical Trial Management Solutions, as analyzed by Maximize Market Research
States) 11. Datatrak International Inc. (United States) Europe 12. ArisGlobal (Ireland) 13. ICON plc (Ireland) 14. CRF Health (Finland) 15. ERT (Germany) 16. Signant Health (United Kingdom) 17. Clinipace (Germany) 18. Anju Software Inc. (Germany) Asia
More news about: Maximize Market Research Pvt. Ltd.
Feb 06, 2026, 08:00 ET Hanbai Motos destaca lançamentos das edições especiais da CG 160 Titan e XR 300L Tornado para o mercado brasileiro
bordo.Já a XR 300L Tornado Special Edition reforça o DNA esportivo da linha Tornado, com grafismos inspirados nas motocicletas de competição da família CRF. O modelo preserva sua proposta versátil, voltada ao uso urbano e fora de estrada, com suspensões de longo curso, chassi de perfil off-road, freios ABS
More news about: Hanbai Motos
Feb 03, 2026, 06:30 ET NEVADA KING EXPANDS SILVER PARK EAST MINERALIZATION WITH 350M STEP-OUT, INTERCEPTS 0.93 G/T AUEQ OVER 14.6M STARTING AT SURFACE
Blast (RAB) samples from the Atlanta Project are split at the drill site and placed in cloth and plastic bags utilizing a nominal 2kg sample weight. CRF standards, blanks, and duplicates are inserted into the sample stream on-site on a one-in-twenty sample basis, meaning all three inserts are included
More news about: Nevada King Gold Corp.
Jan 26, 2026, 11:33 ET Tenstorrent Announces Participation in CHASSIS Program, Joint Initiative for Automotive Chiplet Technology
research organizations (Arteris, Axelera AI, BMW Group, Bosch, CEA, CHIPS-IT, Fraunhofer, imec, Infineon, Menta, NXP, Renault/Ampere, Siemens, Stellantis-CRF and TTTech-Auto) in this initiative to advance automotive chiplet technology.
More news about: Tenstorrent
Jan 22, 2026, 06:00 ET "The Power of Dreams" Behind Breakthrough Performance: Honda Launches Inspiring Campaign as Official Automotive Partner of Team USA
Series Saloon EV modelPowerful racing machines like a Honda IndyCar, ARX-06 and HRC Baja Passport, Civic Type R HRC Rally XP, plus a 2026 CRF250RWE off-road motorcross bikeIn addition to automotive and racing sequences, the campaign includes dedicated creative for Honda Powersports,
More news about: American Honda Motor Co., Inc.
Dec 29, 2025, 06:30 ET NEVADA KING REVIEWS 2025 ACHIEVEMENTS AND 2026 EXPLORATION STRATEGY
Circulation ("RC") samples from Atlanta are split at the drill site and placed in cloth and plastic bags utilizing a nominal 2kg sample weight. CRF standards, blanks, and duplicates are inserted into the sample stream on-site on a one-in-twenty sample basis, meaning all three inserts are included
More news about: Nevada King Gold Corp.
Dec 19, 2025, 07:41 ET Chonnam National University Scientists Discover a Molecular Switch That Protects Crops from Freezing Cold
development," says Prof. Kim.The study also reveals that cold conditions activate cytokinin signaling to induce CRF2, which works together with CRF3. The two genes act as integrators, combining environmental cues with internal hormone signals to fine-tune lateral root initiation
More news about: Chonnam National University